Colon Cancer protects itself by changing the VDR and CYP3A4 genes

Created December 2022

Correlated downregulation of VDR and CYP3A4 in colorectal cancer

Mol Biol Rep . 2022 Dec 5. doi: 10.1007/s11033-022-08141-2 PDF is behind a paywall

Hossein Sadeghi 1 , Veys Hashemnia 2 , Ehsan Nazemalhosseini-Mojarad 3 , Mohammad Reza Ghasemi 2 , Reza Mirfakhraie 4 5

Background: The evidence obtained from experimental studies suggests the tumor-suppressive effects of vitamin D by controlling the differentiation, proliferation, and apoptosis in cancerous cells. Furthermore, the deregulation of genes involved in vitamin D metabolism has been reported in several types of cancer.

Methods: In the present study, we investigated the expression level of vitamin D metabolic pathway genes, including VDR, CYP3A4, RXRa, and GC, in colorectal cancer (CRC) samples compared with the adjacent tissues by using quantitative RT-PCR.

Results: The results indicated significant downregulation of CYP3A4 and VDR genes in CRC tissues compared with the adjacent control tissues (p < 0.01). RXRA and GC expression levels did not show any significant alteration among the studied samples. Moreover, a positive correlation was observed between the expression level of CYP3A4 and VDR genes (p < 0.0001). ROC curve analysis also revealed the potential diagnostic power of CYP3A4 and VDR genes in CRC samples.

Conclusion: Reduction in the expression of both CYP3A4 and VDR plays an important role in CRC due to the possible impairment in vitamin D metabolism. Further studies concerning the relationship between the expression of these genes and colorectal cancer pathogenesis and treatment are recommended.

Butyrate upregulates VDR in the colon

14th activator of the Vitamin D Receptor – Butyrate (from gut bacteria, or supplement)

VitaminDWiki -Some diseases reduce vitamin D getting to blood or cells

{include}

VitaminDWiki - Vitamin D Receptor deactivated by some health problems - many studies

VitaminDWiki - Genetics chart shows the vitamin D genes

image

CYP3A4 (7 as of Dec 2022)

VitaminDWiki - studies in both categories Colon Cancer and Vitamin D Receptor

This list is automatically updated

{category}

92 VitaminDWiki VDR pages have CANCER in title (as of Aug 2025)

This list is automatically updated

{LIST()}

VitaminDWiki - studies in both categories Colon Cancer and Genetics

This list is automatically updated

{category}

VitaminDWiki - Cancer - Colon category contains

{include}

References

  1. Sawicki T, Ruszkowska M, Danielewicz A, Niedzwiedzka E, Arlukowicz T, Przybylowicz KE (2021) A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers 13(9):2025 - DOI - PubMed - PMC

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71(3):209–249 - PubMed

  3. Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przeglad Gastroenterologiczny 14(2):89 - PubMed - PMC

  4. Dolatkhah R, Somi MH, Bonyadi MJ, Asvadi Kermani I, Farassati F, Dastgiri S (2015) Colorectal cancer in Iran: molecular epidemiology and screening strategies. J Cancer Epidemiol 2015:1–10 - DOI

  5. Hong SN (2018) Genetic and epigenetic alterations of colorectal cance r. Intest Res 16(3):327–337. https://doi.org/10.5217/ir.2018.16.3.327 - DOI - PubMed - PMC

  6. Jeon S-M, Shin E (2018) Exploring vitamin D metabolism and function in cancer. Exp Mol Med 50(4):1–14 - PubMed

  7. Boughanem H, Canudas S, Hernandez-Alonso P, Becerra-Tomás N, Babio N, Salas-Salvadó J et al (2021) Vitamin D intake and the risk of colorectal cancer: an updated meta-analysis and systematic review of case-control and prospective cohort studies. Cancers 13(11):2814 - DOI - PubMed - PMC

  8. Sadeghi H, Kamaliyan Z, Mohseni R, Sahebi U, Nazemalhosseini-Mojarad E, Aghaei N et al (2021) Dysregulation of vitamin D synthesis pathway genes in colorectal cancer: a case-control study. J Clin Lab Anal 35(2):e23617 - DOI - PubMed

  9. Afshan FU, Masood A, Nissar B, Chowdri NA, Naykoo NA, Majid M et al (2021) Promoter hypermethylation regulates vitamin D receptor ( VDR ) expression in colorectal cancer-A study from Kashmir valley. Cancer Genet 252–253:96–106. https://doi.org/10.1016/j.cancergen.2021.01.002 - DOI - PubMed

  10. Sadeghi H, Nazemalhosseini-Mojarad E, Sahebi U, Fazeli E, Azizi-Tabesh G, Yassaee VR et al (2021) Novel long noncoding RNAs upregulation may have synergistic effects on the CYP24A1 and PFDN4 biomarker role in human colorectal cancer. J Cell Physiol 236(3):2051–2057 - DOI - PubMed

  11. Sun H, Wang C, Hao M, Sun R, Wang Y, Liu T et al (2016) CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer. Hum Pathol 50:101–108. https://doi.org/10.1016/j.humpath.2015.11.008 - DOI - PubMed

  12. Yi C, Huang C, Wang H, Wang C, Dong L, Gu X et al (2020) Association study between CYP24A1 gene polymorphisms and cancer risk. Pathol Res Pract 216(1):152735. https://doi.org/10.1016/j.prp.2019.152735 - DOI - PubMed

  13. Egan JB, Thompson PA, Ashbeck EL, Conti DV, Duggan D, Hibler E et al (2010) Genetic polymorphisms in vitamin D receptor VDR /RXRA influence the likelihood of colon adenoma recurrence. Can Res 70(4):1496–1504 - DOI

  14. Huang G-L, Chen Q-X, Ma J-J, Sui S-Y, Wang Y-N, Shen D-Y (2019) Retinoic acid receptor a facilitates human colorectal cancer progression via Akt and MMP2 signaling. Onco Targets Ther 12:3087 - DOI - PubMed - PMC

  15. van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH (2019) Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. Cancer Chemother Pharmacol 84(3):487–499 - DOI - PubMed - PMC

  16. Wang Z, Schuetz EG, Xu Y, Thummel KE (2013) Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol 136:54–58 - DOI - PubMed

  17. Bouillon R, Schuit F, Antonio L, Rastinejad F (2020) Vitamin D binding protein: a historic overview. Front Endocrinol 10:910 - DOI

  18. Anic GM, Weinstein SJ, Mondul AM, Männistö S, Albanes D (2014) Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer. PLoS ONE 9(7):e102966 - DOI - PubMed - PMC

  19. Poynter JN, Jacobs ET, Figueiredo JC, Lee WH, Conti DV, Campbell PT et al (2010) Genetic variation in the vitamin D receptor ( VDR ) and the vitamin D–binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry. Cancer Epidemiol Prev Biomark 19(2):525–536 - DOI

  20. Li Z, Jia Z, Gao Y, Xie D, Wei D, Cui J et al (2015) Activation of vitamin D receptor * signaling downregulates the expression of nuclear FOXM1 protein and suppresses *pancreatic cancer cell stemness. Clin Cancer Res 21(4):844–853 - DOI - PubMed

  21. Sana S, Kayani MA (2021) Role of Vitamin D deficiency and mRNA expression of VDR and RXR in haematological cancers. Mol Biol Rep 48(5):4431–4439 - DOI - PubMed

  22. Evans S, Nolla J, Hanfelt J, Shabahang M, Nauta RJ, Shchepotin IB (1998) Vitamin D receptor expression as a predictive marker of biological behavior in human colorectal cancer. Clin Cancer Res 4(7):1591–1595 - PubMed

  23. Saccone D, Asani F, Bornman L (2015) Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. Gene 561(2):171–180 - DOI - PubMed

  24. Thomas M, Sylvester P, Newcomb P, Longman R (1999) Vitamin D receptor expression in colorectal cancer. J Clin Pathol 52(3):181–183 - DOI - PubMed - PMC

  25. Kacevska M, Robertson GR, Clarke SJ, Liddle C (2008) Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 4(2):137–149 - DOI - PubMed

  26. Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C et al (2007) Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer 7(1):1–7 - DOI

  27. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S et al (2005) Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 11(10):3758–3765 - DOI - PubMed

  28. Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K et al (2003) Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 21(13):2481–2485 - DOI - PubMed

  29. Pavek P, Pospechova K, Svecova L, Syrova Z, Stejskalova L, Blazkova J et al (2010) Intestinal cell-specific vitamin D receptor ( VDR )-mediated transcriptional regulation of CYP3A4 gene. Biochem Pharmacol 79(2):277–287 - DOI - PubMed

  30. Roizen JD, Li D, O’Lear L, Javaid MK, Shaw NJ, Ebeling PR et al (2018) CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Investig 128(5):1913–1918 - DOI - PubMed - PMC

  31. Andersen SW, Shu XO, Cai Q, Khankari NK, Steinwandel MD, Jurutka PW et al (2017) Total and free circulating vitamin D and vitamin D-binding protein in relation to colorectal cancer risk in a prospective study of African Americans. Cancer Epidemiol Biomark Prev 26(8):1242–1247 - DOI

  32. Gibbs DC, Bostick RM, McCullough ML, Um CY, Flanders WD, Jenab M et al (2020) Association of prediagnostic vitamin D status with mortality among colorectal cancer patients differs by common, inherited vitamin D-binding protein isoforms. Int J Cancer 147(10):2725–2734 - DOI - PubMed - PMC

  33. Zhang F, Meng F, Li H, Dong Y, Yang W, Han A (2011) Suppression of retinoid X receptor alpha and aberrant ß-catenin expression significantly associates with progression of colorectal carcinoma. Eur J Cancer (Oxf, Engl: 1990). 47(13):2060–2067 - DOI

  34. Wasiewicz T, Piotrowska A, Wierzbicka J (2018) Antiproliferative activity of non-calcemic vitamin D analogs on human melanoma lines in relation to VDR and PDIA3 receptor s. Int J Mol Sci 19(9):2583 - DOI - PubMed - PMC

  35. Ozawa S, Miura T, Terashima J, Habano W (2021) Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resist (Alhambra, Calif) 4(4):946–964

  36. Nallani SC, Goodwin B, Buckley AR, Buckley DJ, Desai PB (2004) Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 54(3):219–229 - DOI - PubMed

Tags: Colon Cancer Genetics Vit D Receptor